



MENARINI
group



COMPANY PROFILE

6th March 2026



1886... 2026...

140 YEARS

**Menarini
was founded in 1886.**

**In 1915 its headquarters
were established
in Florence.**

Milestones

1886

Menarini foundation

1964

International presence

The internationalization of Menarini begins with the opening of **Laboratorios Menarini in Spain**, followed on by **Greece, Portugal, Central America** and **France**.

1978

Research & Development

Menarini's Research & Development department opened and patents on pharmaceuticals were introduced.

1992

Central and Eastern Europe

Menarini acquires ex-GDR company **Berlin-Chemie** thanks to which it makes its entry into **Germany** and Central and Eastern Europe.

Since 1992, the Menarini Group has reinvested all profits in its growth

2003

Menarini Biotech

Opening of Menarini Biotech, specialised in the research, development and manufacturing of biotech pharmaceuticals, from the lab to the patient.

Milestones

2011

Asia Pacific

Menarini makes its entry into Asia Pacific thanks to the acquisition of a company based in **Singapore** and present in **13 countries** throughout the region, from China to Australia.

2013-2016

Silicon Biosystems

Acquisition of Silicon Biosystems, a start-up of innovative technologies for liquid biopsies.

Cellsearch

Acquisition of Cell Search, an FDA approved technology in the field of **circulating tumor cells**.

2020

U.S.A.

Menarini makes its entrance into the USA through to the acquisition of **Stemline Therapeutics**, biopharmaceutical company publicly listed on NASDAQ, and their product **Tagraxofusp**, the only FDA approved therapy available for BPDCN, thus strengthening Menarini's presence in oncology.


2023

FDA & EMA



U.S. FDA and EU (EMA) approve **Elacestrant** as the first treatment for patients with ER+/HER2-, ESR1 mutated advanced or metastatic breast cancer.

Consolidated turnover

Million euro



Consolidated turnover




Menarini in the world


Present in **140 countries** worldwide (with its affiliates, distributors and franchises)



Number of employees



Employees % of graduates and technicians



18 manufacturing plants*

EUROPE is the Group's heart of production

Italy	Pisa (2 plants), Florence (2 plants) Pomezia**, L'Aquila, Lomagna (Lecco), Casaletto Lodigiano (Lodi)
Spain	Barcelona
Germany	Berlin (2 plants), Dresden



Plants dedicated to the **production for local markets** are located in Central America (Guatemala City), Ireland (Shannon), Turkey (Istanbul), Russia (Kaluga) and Indonesia (Jakarta)

U.S.A. (Philadelphia - Huntingdon Valley): **diagnostic production**



9 Research & Development centers



Research & Development Projects

ONCOLOGY

SOLID TUMORS	COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
	Elacestrant ^o	SME (SERD - ER)	Monotherapy: ER+/HER2- Metastatic Breast Cancer (<i>EMERALD</i> trial)	EMA and FDA: approved
	Elacestrant	SME (SERD - ER)	Monotherapy: CDK4/6 Inhibitor-naïve ER+/HER2- Metastatic Breast Cancer (<i>ELCIN</i> trial)	Phase II
	Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic Breast Cancer (<i>ELEVATE</i> trial)	Phase II
	Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Breast Cancer with brain metastasis (<i>ELECTRA</i> trial)	Phase II
	Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic or locally Advanced Breast Cancer (<i>SUMIT-ELA</i> trial)*	Phase II
	Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- , ESR-1 mut, Advanced Breast Cancer (<i>ADELA</i> trial)**	Phase III
	Elacestrant	SME (SERD - ER)	Monotherapy: ER+/HER2- early Breast Cancer with a high risk of recurrence (<i>ELEGANT</i> trial)	Phase III
	SL-701	IT (IL-13Ra2, EphA2, Survivin)	Recurrent Glioblastoma	Phase II
	MEN1309	ADC (Anti-CD205)	Solid Tumors	Phase Ib
MEN2312	SME (KAT6i)	Breast Cancer/Solid Tumors and HEME malignancies	Phase I	
Selinexor	SME (XP01i)	Endometrial Cancer***	Phase III	
MEN2501	SME (KIF18Ai)	Ovarian Cancer	Phase I	
MEN2602	Biologic	Multiple Tumors	Pre-clinical	

HEMATOLOGY	COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
	Tagraxofusp	TB (CD123)	Monotherapy: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	EMA and FDA: approved
	Tagraxofusp	TB (CD123)	Monotherapy: Chronic myelomonocytic leukemia (CMML)	Phase II
	Tagraxofusp	TB (CD123)	Monotherapy: Myelofibrosis (MF)	Phase II
	Tagraxofusp	TB (CD123)	Combination therapy: Acute Myeloid Leukemia (AML)	Phase II
	MEN1703	SME (PIM/FLT3i)	Monotherapy: Relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL)	Phase II
	Selinexor ^{oo}	SME (XP01i)	Combination therapy: Relapsed/refractory Multiple Myeloma***	EMA and FDA*: approved
	Selinexor	SME (XP01i)	Combination therapy: Myelofibrosis***	Phase III

^o <https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation>

* In collaboration with Carrick Therapeutics

** In co-sponsorship with MedSir

*** Karyopharm trial. Based on the Licensing agreement in force, Menarini has Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries

** <https://www.menarini.com/en-us/news/news-detail/karyopharm-and-menarini-receive-full-marketing-authorisation-from-the-european-commission-for-nexpovio174-selinexor-for-the-treatment-of-patients-with-multiple-myeloma-after-at-least-one-prior-therapy.html>

Commercialized by the Licensor: Karyopharm Therapeutics



Research & Development Projects

ANTI-INFECTIVES

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
Meropenem + Vaborbactam	Carbapenem + β -lactamase inhibitor	Complicated urinary tract infections, Complicated Intra abdominal infections, Hospital acquired pneumonia, Ventilator associated pneumonia and Bacteremia	EMA, FDA*, Hong Kong, Malaysia, Singapore, Thailand, Macao, Switzerland: approved
Delafloxacin	Anionic fluoroquinolone	Acute Bacterial Skin and Skin Structure - ABSSSI Community Acquired Bacterial Pneumonia - CABP	EMA, FDA*, Hong Kong, Switzerland, TITCK (Turkey): approved
Oritavancin	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA, FDA*, Switzerland: approved
Oritavancin (1 vial formulation)	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA, FDA*, Switzerland: approved

Research & Development Projects

CARDIO-METABOLIC

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
Obicetrapib	Cholesteryl ester transfer protein (CETP) inhibitor	Lipid Lowering agent administered to patients previously treated with Maximum Tolerated Lipid-Modifying Therapies not at target for LDL-C	Phase III completed, under EU review
		Prevention of Major Adverse CardioVascular events	Phase III
Obicetrapib+Ezetimibe	Cholesteryl ester transfer protein (CETP) inhibitor + Niemann-Pick C1-like 1 (NPC1L1) protein inhibitor	Lipid Lowering agent administered to patients treated with Maximum Tolerated Lipid-Modifying Therapies not at target for LDL-C	Phase III completed, under EU review

Menarini for People: our Social Responsibility projects



Wheelchair basketball

Volpi Rosse Menarini
Menarini Joventut. *When sport can help break down barriers and foster inclusion and independence.*



A pediatrician's network

Help up 15,000 "sentinel doctors" recognise child abuse.



Social Enterprise Department

A special department in Berlin-Chemie Menarini, where about 30 people with physical and intellectual disabilities are involved in daily work.



Menarini Forest

17,800 trees planted in several countries all over the world.



Standing by children in difficulty

Healthcare, nutrition and education for children from economically disadvantaged families.



Donations of medicines

Community of Sant'Egidio, ManzAid Association.

Fondazione Menarini

The **Fondazione Menarini** was founded in 1976 to promote research and knowledge in the fields of biology, pharmacology and medicine, as well as economy and human sciences.



**FONDAZIONE
MENARINI**

Events

More than 600 International Events, 2.000 Speakers and 75.000 attendees.
Live streaming in 3 languages.



“Think Tank” which, since 2022, promotes initiatives for change on social, economic and cultural issues in Italy.

House of Sciences

More than 3.000 articles available free of charge and video interviews with 10 Nobel laureates.

- **Scientific Library** - 8 therapeutic areas
- **Dialogs Beyond Borders** - video interviews

Minuti



- **Minuti Science** - Website dedicated to Minuti Science edition.
- **Minuti Art** - Website dedicated to Minuti Art edition.

Fair Play Menarini International Award

Ethics, Loyalty, Respect



Now in its 30th edition, the **Fair Play Menarini International Award** promotes the fundamental values of sport.

The award winners become **Fair Play Ambassadors**, symbolising outstanding sporting feats achieved in the name of fair play and respect.

Over 400 award winners, including: Stefan Edberg, Casey Stoner, Ian Thorpe, Federica Pellegrini, Edwin Moses, Tommie Smith, Luis Figo and Zico.



MENARINI
group

